The 2010 Cantech Letter Awards: The Nominees

December 15, 2010 By 1 Comment
Mark Therier, President and CEO of SXC Health

When we decided to hold the first ever Cantech Letter Awards we were immediately faced with some tough choices. How many categories should there be? Which companies should be eligible? Should we simply take the ten best performing stocks and let our readers vote on them? What about revenue growth, is that more important than share price? Perhaps a combination of the two? Should a percentage gain in either be weighted more heavily to larger stocks? In the end we decided on two categories: Canadian Technology Stock of the Year and Canadian Technology Executive of the Year. We also invited a panel of judges to help us to not only choose the winners, but also the candidates…

Filed Under: Lists and Data Tagged With: , , , , , , , , ,

DragonWave roars back on Clearwire clarity

December 11, 2010 By Leave a Comment
DragonWave President and CEO Peter Allen

Shares of DragonWave (TSX:DWI) have roared back to life this December, closing over the $9 dollar mark for the first time since April. DragonWave’s incredible run of 2009, in which the company went from trading under a dollar on the Canadian Venture exchange to a full NASDAQ listing and share price over (US) $13, was [...]

Filed Under: Wireless Tagged With:

Open Text tackles enterprise security in a WikiLeaks world

December 9, 2010 By Leave a Comment
John Shackleton, President and CEO of Waterloo's Open Text (TSX:OTC)

You can’t open a paper or turn on a TV without hearing about Australian Julian Assange and his guerrilla style news organization WikiLeaks. Public opinion has become sharply divided over whether the organization provides a valuable service to society or threatens national security. What has become increasingly clear is that Wiki-leaks does represent a Tipping [...]

Filed Under: IT, Tech Triangle, Wireless Tagged With:

Can Sandvine help Save the Internet?

December 7, 2010 By Leave a Comment
DaveCaputo2

When Sandvine President and CEO Dave Caputo picks up a newspaper these days it must be hard to stop smiling. Two contentious, consumer-related technology issues keep landing on editorial pages, and his company is in the sweet spot for both. The first has to do with what the FCC calls “Bill Shock”. It’s estimated that [...]

Filed Under: Tech Triangle, Wireless Tagged With:

Are things finally looking up for AEterna Zentaris?

December 5, 2010 By Leave a Comment
Jürgen Engel, President & CEO of AEterna Zentaris

Early this year, things weren’t looking that great for Quebec City’s AEterna Zentaris (TSX:AEZ). On January 21st, the company received notification from the NASDAQ that they didn’t comply with the exchange’s minimum bid price requirements. Shares of AEterna, an oncology and endocrine therapy drug development company with a Phase 3 cancer therapy candidate, Perifosine, had [...]

Filed Under: Life Sciences Tagged With:

Is RIM set to make an astonishing comeback with The Astonishing Tribe?

December 3, 2010 By Leave a Comment
theastonishingtribe

Research in Motion completed another acquisition yesterday, and once again the move has tech geeks buzzing more than those who know the company by ticker symbol first. TAT, an acronym for The Astonishing Tribe is a company that was formed in Malmo, Sweden in 2002. TAT got a foothold in the rendering and structuring of [...]

Filed Under: RIM, Tech Triangle Tagged With:

NEO Material goes Back to the Future with rare earth deal

December 2, 2010 By Leave a Comment
Neo Material's CEO Constantine Karayannopoulos speaks with BNN's Andrew Bell on July 14th, 2010

A cell phone the size of a shoe. A laptop that weighs more than a truck tire. If it weren’t for rare earth metals, a collection of seventeen chemical elements in the periodic table that are generally found in ore deposits, technology as we know it today would be whole lot different. Rare earth metals [...]

Filed Under: Cleantech Tagged With:

Cantech Letter interviews Industry Minister Tony Clement

December 1, 2010 By Leave a Comment
DecemberCover1

It’s been nearly a century since Canada’s greatest achievement in biotech took place; the discovery of insulin by Frederick Banting and his assistant Charles Best, in 1922. While nothing since has matched that miraculous feat, which has saved countless millions of lives, it’s not like Canada has been sitting still in the meantime. Canadian researchers have contributed to The Human Genome project, cracked the genetic code of the mosquito that carries the deadliest strain of malaria, and deciphered human chromosome 7, which holds the gene for cystic fibrosis. Our December issue is about Canadian Life Sciences stocks carrying the torch of innovation.

Filed Under: Interviews, Life Sciences Tagged With: , , ,

10 Canadian Life Sciences Stocks that could Change the World

December 1, 2010 By Leave a Comment
Oncolytics Thompson: "The value of the head and neck cancer market is in the US$300 to US$500 million globally and we believe REOLYSIN® can address a significant portion of this market."

It’s been nearly a century since Canada’s greatest achievement in biotech took place; the discovery of insulin by Frederick Banting and his assistant Charles Best, in 1922. While nothing since has matched that miraculous feat, which has saved countless millions of lives, it’s not like Canada has been sitting still in the meantime. Canadian researchers [...]

Filed Under: Life Sciences, Lists and Data Tagged With: , , , , , , , , ,

Cantech Letter interviews Brad Thompson President and CEO of Oncolytics Biotech

December 1, 2010 By Leave a Comment
Oncolytics Thompson: "The value of the head and neck cancer market is in the US$300 to US$500 million globally and we believe REOLYSIN® can address a significant portion of this market."

Calgary’s Oncolytics Biotech grew out of discoveries made in the 1990′s in the Department of Microbiology and Infectious Diseases at the University of Calgary. The Company’s Reolysin, a formulation of reovirus, a family of viruses that can affect the gastrointestinal system and have shown to have oncolytic, or cancer killing properties, is about to enter [...]

Filed Under: Interviews, Life Sciences Tagged With: